MX2022001736A - Formulaciones y tratamientos topicos. - Google Patents

Formulaciones y tratamientos topicos.

Info

Publication number
MX2022001736A
MX2022001736A MX2022001736A MX2022001736A MX2022001736A MX 2022001736 A MX2022001736 A MX 2022001736A MX 2022001736 A MX2022001736 A MX 2022001736A MX 2022001736 A MX2022001736 A MX 2022001736A MX 2022001736 A MX2022001736 A MX 2022001736A
Authority
MX
Mexico
Prior art keywords
weight parts
pharmaceutical formulation
treatments
topical formulations
pharmaceutical
Prior art date
Application number
MX2022001736A
Other languages
English (en)
Inventor
Hemant H Alur
James A H Harwick
Original Assignee
Trilogic Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trilogic Pharma Llc filed Critical Trilogic Pharma Llc
Publication of MX2022001736A publication Critical patent/MX2022001736A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporciona una formulación farmacéutica y un método asociado con la misma para tratar vaginosis bacteriana. La formulación farmacéutica incluye de 10 a 25 partes en peso de poloxámero F127, de 0.5 a 3.0 partes en peso de goma de xantano, de 70 a 90 partes en peso de agua, y una cantidad terapéuticamente efectiva de un ingrediente activo farmacéutico. La formulación farmacéutica también puede incluir de 0.5 a 1.5 partes en peso de alcohol bencílico.
MX2022001736A 2015-07-20 2018-01-18 Formulaciones y tratamientos topicos. MX2022001736A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562194518P 2015-07-20 2015-07-20

Publications (1)

Publication Number Publication Date
MX2022001736A true MX2022001736A (es) 2022-03-11

Family

ID=57835134

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018000800A MX2018000800A (es) 2015-07-20 2016-07-18 Formulaciones y tratamientos topicos.
MX2022001736A MX2022001736A (es) 2015-07-20 2018-01-18 Formulaciones y tratamientos topicos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018000800A MX2018000800A (es) 2015-07-20 2016-07-18 Formulaciones y tratamientos topicos.

Country Status (11)

Country Link
US (2) US11129896B2 (es)
EP (1) EP3324938B1 (es)
CA (2) CA3209380A1 (es)
DK (1) DK3324938T3 (es)
ES (1) ES2891754T3 (es)
HU (1) HUE056401T2 (es)
LT (1) LT3324938T (es)
MX (2) MX2018000800A (es)
PL (1) PL3324938T3 (es)
PT (1) PT3324938T (es)
WO (1) WO2017015232A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018015143A2 (pt) 2016-02-09 2018-12-18 Bracco Suisse Sa proteína quimérica recombinante para direcionamento de selectinas
US20240165141A1 (en) * 2021-07-26 2024-05-23 Daré Bioscience, Inc. Systems and methods for treatment of bacterial vaginosis
JP2024529479A (ja) * 2021-07-26 2024-08-06 デア バイオサイエンス， インコーポレイテッド 膣挿入のための組成物及び技術
WO2024155775A2 (en) * 2023-01-19 2024-07-25 Dare Bioscience, Inc. Compositions and techniques for treatment of polycystic ovarian syndrome (pcos) and endometriosis
WO2024155777A2 (en) * 2023-01-19 2024-07-25 Dare Bioscience, Inc. Compositions and techniques for treatment of polycystic ovarian syndrome (pcos) and endometriosis
WO2024158951A2 (en) * 2023-01-25 2024-08-02 Dare Bioscience, Inc. Compositions and methods for treating dysmenorrhea

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1120001C (zh) * 1997-11-24 2003-09-03 曾忠铭 刺激阴道革兰氏阳性杆菌生长、增强阴道酸度的药剂和其用途
US20040167223A1 (en) * 2002-09-03 2004-08-26 Popp Karl F. Topical antibacterial formulations
CN1311873C (zh) * 2004-06-30 2007-04-25 上海复康医药科技发展有限公司 一种温度敏感的阴道用原位凝胶制剂
WO2009073658A1 (en) * 2007-12-03 2009-06-11 Trilogic Pharma Llc Self solidifying bioerodible barrier implant
WO2009090558A2 (en) * 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US20100105750A1 (en) 2008-10-23 2010-04-29 Nycomed Us Inc. Stable metronidazole gel formulations
CN102525884A (zh) 2010-12-19 2012-07-04 复旦大学 一种用于阴道给药的温敏原位凝胶制剂

Also Published As

Publication number Publication date
ES2891754T3 (es) 2022-01-31
CA2993012A1 (en) 2017-01-26
US20180207275A1 (en) 2018-07-26
WO2017015232A1 (en) 2017-01-26
US11129896B2 (en) 2021-09-28
CA2993012C (en) 2023-10-03
PL3324938T3 (pl) 2022-01-10
EP3324938A1 (en) 2018-05-30
EP3324938A4 (en) 2019-03-13
EP3324938B1 (en) 2021-09-01
US20220040306A1 (en) 2022-02-10
CA3209380A1 (en) 2017-01-26
LT3324938T (lt) 2021-11-25
DK3324938T3 (da) 2021-09-27
MX2018000800A (es) 2018-08-16
PT3324938T (pt) 2021-09-21
HUE056401T2 (hu) 2022-02-28

Similar Documents

Publication Publication Date Title
MX2022001736A (es) Formulaciones y tratamientos topicos.
MX2016009666A (es) Suministro topico de composiciones para la piel que tienen ph bajo.
NZ761388A (en) Methods of treatment for cystic fibrosis
MX2021006035A (es) Formulaciones cannabinoides estables.
MX2021013139A (es) Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
WO2013090278A3 (en) Intranasal dexmedetomidine compositions and methods of use thereof
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
CL2019002172A1 (es) Agente terapéutico para enfermedades del hígado.
CR20170604A (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma
SA113340494B1 (ar) تركيبة لعلاج اضطرابات أيضية
EP4397375A3 (en) Isoxazoline parasiticide formulations and methods for treating blepharitis
MX2019006773A (es) Dexmedetomidina o medetomidina para uso en el tratamiento de la ansiedad por separacion en perros.
MX2016016400A (es) Formulaciones de oximetazolina estabilizadas y sus usos.
SG10201908690WA (en) Novel method of use and compositions
MX2019008115A (es) Formulaciones topicas de detomidina.
MX2020005921A (es) Formulaciones y metodos para el suministro vaginal de antiprogestinas.
MX2020000164A (es) Formulaciones de isotretinoína para la mucosa oral y métodos para usar las mismas.
MX2018011539A (es) Tratamiento de dolencias y enfermedades cutaneas asociadas a biopeliculas microbianas.
UY37867A (es) Formulación de uso tópico para el control y la prevención de parásitos en animales
GR1008819B (el) Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου
MX2017011425A (es) Formulacion cosmetica antioxidante para uso topico que comprende una asociacion de extractos de plantas y uso de la misma.
MX2015016678A (es) Formulaciones farmaceuticas que comprenden agomelatina en forma de cocristal de agomelatina con un acido organico.
MX2017014471A (es) Clonidina y/o derivados de clonidina para uso en la prevención de la lesión de la piel resultante de la radioterapia.
ZA202102913B (en) Dosage regime
WO2016115442A3 (en) Therapeutic protein formulations